Aclaris data positive despite patient withdrawals, says Cantor Fitzgerald

Aclaris Therapeutics’ data for ATI-502 were positive, despite patient withdrawals by participants that were typically lost to follow-up or who withdrew due to lack of effect, Cantor Fitzgerald analyst Louise Chen tells investors in a research note titled “Don’t Need a Gingerbread Man to Make Your Life Sweet; Catch ACRS’s Stock Instead.” She believes the positive updates underscore that Aclaris’ drugs “can treat tough patient populations and provide a positive read-through to additional readouts coming in 2019.” The data also demonstrate that a topical JAK can work, contends the analyst. Chen keeps an Overweight rating on Aclaris Therapeutics with a $50 price target.
https://thefly.com/landingPageNews.php?id=2838623